591 upcoming catalysts — clinical readouts, PDUFA dates, FDA decisions, and conference data cuts — ranked by importance and searchable by company, asset, or therapeutic area. 8 verified · 583 live-sourced.
591 catalysts · showing first 25
VKTX·VK2735 (oral)
Market Moving
Clinical ReadoutMetabolicPhase 3
Obesity
ExpectedQ3 2026· Confirmed
PoSⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
65%
Why It Matters
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Verified ↗Details →VerifiedEditor-reviewed catalyst with confirmed or carefully validated timing, source context, and executive summary.
REGN·Dupixent (IL-4Rα)
Market Moving
FDA DecisionRespiratoryRegistration
COPD
ExpectedQ3 2026· Confirmed
PoSⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
80%
Why It Matters
First biologic approved for COPD would open a massive new market. Commercial peak sales estimates of $3B+ annually. Eosinophilic COPD subgroup most likely to benefit.
Verified ↗Details →VerifiedEditor-reviewed catalyst with confirmed or carefully validated timing, source context, and executive summary.
LLY·Tirzepatide
Important
Clinical ReadoutCardiovascularPhase 3
Heart Failure with Preserved EF
ExpectedH2 2026· Confirmed
PoSⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
60%
Why It Matters
HFpEF has no approved pharmacological treatments. Positive data would expand GLP-1 addressable market substantially and reinforce cardiovascular benefits beyond weight loss.
Verified ↗Details →VerifiedEditor-reviewed catalyst with confirmed or carefully validated timing, source context, and executive summary.
·Xanamem
Important
Clinical ReadoutCNSPhase 2/Phase 3
Dementia Moderate
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·BHV-7000
Important
Clinical ReadoutCNSPhase 2/Phase 3
Focal Epilepsy
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Abiraterone - Usual
Important
Clinical ReadoutOncologyPhase 2/Phase 3
Prostate Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·ETOPOSIDE - Usual
Important
Clinical ReadoutOncologyPhase 2/Phase 3
Small Cell Lung Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·ALECENSA - alectinib hydrochloride capsule
Important
Clinical ReadoutOncologyPhase 2/Phase 3
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Selinexor (combination therapy)
Important
Clinical ReadoutOncologyPhase 2/Phase 3
Relapsed/Refractory Diffuse Large B-cell Lymphoma
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Raloxifene - Usual
Important
Clinical ReadoutOncologyPhase 2/Phase 3
Breast Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Durvalumab
Important
Clinical ReadoutOncologyPhase 3
Hepatocellular Carcinoma
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Durvalumab
Important
Clinical ReadoutOncologyPhase 3
Non-Small Cell Lung Cancer
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Zanidatamab
Important
Clinical ReadoutOncologyPhase 3
Gastric Neoplasms
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Entrectinib
Important
Clinical ReadoutOncologyPhase 3
Carcinoma, Non-Small-Cell Lung
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Pemetrexed
Important
Clinical ReadoutOncologyPhase 3
Non-Small Cell Lung Cancer
ExpectedQ3 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·[O-15]-Water PET Myocardial Perfusion Imaging (MPI)
Important
Clinical ReadoutCardiovascularPhase 3
Coronary Artery Disease
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
56%
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·AK112, Gemcitabine, Cisplatin
Important
Clinical ReadoutOncologyPhase 3
Biliary Tract Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Pirtobrutinib
Important
Clinical ReadoutOncologyPhase 3
Chronic Lymphocytic Leukemia
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·BL-M07D1
Important
Clinical ReadoutOncologyPhase 3
HER2-positive Breast Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Ziltivekimab
Important
Clinical ReadoutCardiovascularPhase 3
Heart Failure
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
56%
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Apalutamide
Important
Clinical ReadoutOncologyPhase 3
Metastatic Castrate-sensitive Prostate Cancer
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Atezolizumab
Important
Clinical ReadoutOncologyPhase 3
Unresectable Hepatocellular Carcinoma
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Milvexian
Important
Clinical ReadoutCardiovascularPhase 3
Ischemic Stroke; Ischemic Attack, Transient
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
56%
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Ocrelizumab
Important
Clinical ReadoutCNSPhase 3
Progressive Multiple Sclerosis (PMS)
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
52%
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
·Inclisiran sodium 300 mg
Important
Clinical ReadoutCardiovascularPhase 3
Coronary Artery Disease
ExpectedQ4 2026· Est.
PoSest.ⓘProbability of Success — illustrative analyst consensus estimate. Not primary research. Always verify with company filings, ClinicalTrials.gov, and FDA.gov.
56%
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
ClinicalTrials.gov ↗Details →Live-SourcedPulled from public data sources and refreshed periodically. Timing and details should be independently verified.
Verified: Editor-reviewed catalyst with validated timing, source context, and executive summary.
Live-Sourced: Pulled from public data sources and refreshed periodically. Timing and details should be independently verified.
PoS estimates are illustrative figures based on BIO/IQVIA phase benchmarks — not primary research. Click any catalyst to view full program details.